Cytokinetics(US:CYTK) Globenewswire·2025-11-05 22:54Core Viewpoint - The Gross Law Firm is notifying shareholders of Cytokinetics, Incorporated regarding a class action lawsuit related to misleading statements about the New Drug Application (NDA) for aficamten, which may have led to inflated stock prices and subsequent losses for investors [1][3]. Group 1: Allegations and Timeline - The class period for the lawsuit is from December 27, 2023, to May 6, 2025 [3]. - Allegations include that Cytokinetics made materially false and misleading statements about the NDA submission timeline and approval process for aficamten, specifically expecting FDA approval in the second half of 2025 based on a September 26, 2025 PDUFA date [3]. - The company failed to disclose risks related to not submitting a Risk Evaluation and Mitigation Strategy (REMS), which could delay the regulatory process [3]. Group 2: Impact on Shareholders - On May 6, 2025, it was revealed during an earnings call that the company had discussions with the FDA regarding safety monitoring and risk mitigation but chose to submit the NDA without a REMS, misleading investors about the regulatory timeline [3]. - As a result of these misleading statements, shareholders purchased Cytokinetics' common stock at artificially inflated prices and suffered significant losses when the truth was revealed [3]. Group 3: Next Steps for Shareholders - The deadline for shareholders to register for the class action is November 17, 2025, and they are encouraged to register to monitor the case's progress [4]. - There is no cost or obligation for shareholders to participate in the case, and they will be enrolled in a portfolio monitoring software for updates [4]. Group 4: Law Firm's Commitment - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights and ensuring companies adhere to responsible business practices [5]. - The firm seeks recovery for investors who incurred losses due to false or misleading statements or omissions of material information that led to stock price inflation [5].